Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,443 across all filing types
Latest filing 2018-06-06 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Imugene Entitlement Offer notice to eligible shareholders 4 pages 314.1KB
Capital/Financing Update Classification · 95% confidence The document is a detailed notice to shareholders about an entitlement offer, describing the terms, eligibility, timetable, and purpose of the equity raising. It includes information about the placement, the non-renounceable entitlement offer, and instructions for shareholders. There is no financial statement or report content, but rather an announcement of a capital raising event. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document length is sufficient and contains substantive details about the financing event, not just a brief mention or a link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is CAP with high confidence.
2018-06-06 English
Imugene Entitlement Offer notice to ineligible shareholders 3 pages 309.5KB
Capital/Financing Update Classification · 95% confidence The document is a letter dated 7 June 2018 from Imugene Limited to shareholders, specifically addressing an entitlement offer related to a $20.1 million equity raising. It details the terms of the entitlement offer, eligibility criteria for shareholders, and the use of proceeds. The document is an announcement about a capital raising event, including placement and entitlement offer details, underwriting, and shareholder eligibility. There is no financial statement or detailed financial report included, only information about the capital raising and share issuance terms. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories like Annual Report or Earnings Release. The document length is 5814 characters, which is sufficient for a detailed announcement but does not contain financial statements or management discussion. Therefore, the correct classification is Capital/Financing Update (CAP).
2018-06-06 English
Imugene Entitlement Offer notice to option holders 3 pages 310.4KB
Capital/Financing Update Classification · 95% confidence The document is a notice to option holders regarding an entitlement offer and a placement to raise equity capital. It details the terms of the equity raising, the rights of option holders, and instructions on exercising options to participate in the entitlement offer. There are no financial statements, earnings data, or management discussion of financial results. The document is an announcement about a capital raising event and instructions related to share options, which fits the category of Capital/Financing Update (CAP). The document length is about 5,395 characters, which is sufficient for a detailed announcement but does not contain a full financial report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2018-06-06 English
Notice of General Meeting/Proxy Form 12 pages 1.2MB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice of General Meeting for Imugene Limited, detailing resolutions for shareholder approval regarding the allotment and issue of shares and options under a placement, ratification of previous share and option issues, and related voting exclusions. It includes an explanatory memorandum explaining the purpose of the resolutions, the use of funds, and directors' recommendations. The content focuses on shareholder meeting notices and resolutions related to capital raising and share issuance approvals. This fits the definition of a Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting. It is not an actual financial report, earnings release, or capital update announcement, but a formal meeting notice with explanatory details for voting purposes.
2018-06-06 English
Trading Halt 2 pages 454.1KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Imugene Limited regarding a trading halt requested by the company pending the release of an announcement about a material acquisition and associated capital raising. It is dated 5 June 2018 and references compliance with ASX Listing Rule 17.1. The content is a formal notification of a trading halt, not the actual announcement of the acquisition or capital raising itself. The document length is short (1933 characters), and it does not contain financial data or detailed report content. Therefore, it is an announcement related to capital/financing activity but specifically about the trading halt, which is a regulatory announcement. Given the nature of the document as a trading halt notice pending a capital raising announcement, the best fitting category is Capital/Financing Update (CAP).
2018-06-04 English
Appendix 4C - quarterly 5 pages 672.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed quarterly financial data including cash flows from operating, investing, and financing activities, as well as reconciliation of cash and cash equivalents. It references a specific quarter ended 31 March 2018 and includes actual financial figures and notes. The document is about a quarterly report with substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2018
2018-04-25 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.